CN111566207A - 工程化的dna酶酶及其在疗法中的用途 - Google Patents

工程化的dna酶酶及其在疗法中的用途 Download PDF

Info

Publication number
CN111566207A
CN111566207A CN201880068103.8A CN201880068103A CN111566207A CN 111566207 A CN111566207 A CN 111566207A CN 201880068103 A CN201880068103 A CN 201880068103A CN 111566207 A CN111566207 A CN 111566207A
Authority
CN
China
Prior art keywords
seq
dnase
enzyme
variant
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880068103.8A
Other languages
English (en)
Chinese (zh)
Inventor
托碧昂斯·A·富驰
米格尔·吉姆茨-阿卡兹
约瑟芬·戈贝尔(原名:约瑟芬·贝特灵)
汉娜·恩格勒特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutrex Co ltd
Original Assignee
Neutrex Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutrex Co ltd filed Critical Neutrex Co ltd
Publication of CN111566207A publication Critical patent/CN111566207A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880068103.8A 2017-08-18 2018-08-20 工程化的dna酶酶及其在疗法中的用途 Pending CN111566207A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762547220P 2017-08-18 2017-08-18
US62/547,220 2017-08-18
US201762611166P 2017-12-28 2017-12-28
US62/611,166 2017-12-28
PCT/US2018/047084 WO2019036719A2 (en) 2017-08-18 2018-08-20 GENETICALLY MODIFIED DNASE ENZYMES AND THEIR USE IN THERAPY

Publications (1)

Publication Number Publication Date
CN111566207A true CN111566207A (zh) 2020-08-21

Family

ID=65362608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880068103.8A Pending CN111566207A (zh) 2017-08-18 2018-08-20 工程化的dna酶酶及其在疗法中的用途

Country Status (15)

Country Link
US (5) US10696956B2 (https=)
EP (2) EP3668972B8 (https=)
JP (1) JP7577314B2 (https=)
KR (2) KR20250073498A (https=)
CN (1) CN111566207A (https=)
AU (1) AU2018318313B2 (https=)
BR (1) BR112020003403A2 (https=)
CA (1) CA3073317A1 (https=)
DK (1) DK3668972T3 (https=)
ES (1) ES3008982T3 (https=)
IL (2) IL272715B2 (https=)
MX (1) MX2020001913A (https=)
SG (1) SG11202001445XA (https=)
UA (1) UA129696C2 (https=)
WO (1) WO2019036719A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
EP3351263A1 (en) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
DK3668972T3 (da) 2017-08-18 2025-01-13 Neutrolis Inc Konstruerede dnase-enzymer og anvendelse i terapi
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
IL325846A (en) * 2018-10-08 2026-03-01 Neutrolis Inc Engineering deoxyribonuclease enzymes for manufacturing and medicine
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
WO2020227415A1 (en) * 2019-05-06 2020-11-12 President And Fellows Of Harvard College Dna-degrading proteins and uses thereof
WO2021071733A1 (en) * 2019-10-07 2021-04-15 Texas Tech University System Mutant dnase1l3 with improved serum half-life
IL294114A (en) * 2020-01-11 2022-08-01 Univ Yale Preparations and methods for the treatment, improvement and/or prevention of diseases or disorders caused by or related to dnase1 and/or dnase1l3
WO2021168413A1 (en) * 2020-02-20 2021-08-26 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
US20230174944A1 (en) * 2020-04-15 2023-06-08 Cartesian Therapeutics, Inc. Engineered cells secreting therapeutic enzymes
US20230226138A1 (en) * 2020-06-01 2023-07-20 Black Cat Bio Limited Compositions and methods for treating infections and netopathy
EP4161645A4 (en) * 2020-06-08 2023-11-01 Yale University COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING COAGULOPATHY AND/OR SEPSIS IN PATIENTS WITH BACTERIAL AND/OR VIRAL INFECTIONS
EP4225903A1 (en) 2020-10-07 2023-08-16 Protalix Ltd. Long-acting dnase
WO2025076525A1 (en) * 2023-10-06 2025-04-10 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770533A (zh) * 2009-11-02 2012-11-07 华盛顿大学 治疗性核酸酶组合物和方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6656685B2 (en) 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US20040138156A1 (en) 2002-02-26 2004-07-15 Schneider Michael C Therapeutic regulation of deoxyribonuclease-1-like-3 activity
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
US20090305345A1 (en) 2006-10-23 2009-12-10 Medical Research Council Polymerase
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
WO2012106264A2 (en) 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
US9867871B2 (en) 2011-12-12 2018-01-16 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
CA2935748A1 (en) * 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107249621A (zh) 2014-09-08 2017-10-13 哥谭生物制药股份有限公司 用于治疗肺结节病的粘液溶解剂
WO2016118476A1 (en) 2015-01-20 2016-07-28 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
CA3036926C (en) 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
EP3570667B1 (en) 2017-01-20 2022-11-16 Neutrolis Inc. Animal model for drug development
DK3668972T3 (da) 2017-08-18 2025-01-13 Neutrolis Inc Konstruerede dnase-enzymer og anvendelse i terapi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102770533A (zh) * 2009-11-02 2012-11-07 华盛顿大学 治疗性核酸酶组合物和方法
US20150037871A1 (en) * 2009-11-02 2015-02-05 University Of Washington Therapeutic nuclease compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREW WILBER: "Deoxyribonuclease 1 -like III is an inducible macrophage barrier to liposomal transfection" *
JIMENEZ-ALCAZAR M: "Impaired DNasel -mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies" *
VANJA SISIRAK: "Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity" *

Also Published As

Publication number Publication date
AU2018318313B2 (en) 2025-01-23
MX2020001913A (es) 2020-09-07
KR20250073498A (ko) 2025-05-27
IL317968A (en) 2025-02-01
US20210277372A1 (en) 2021-09-09
WO2019036719A3 (en) 2019-03-28
IL272715A (en) 2020-04-30
EP3668972B1 (en) 2024-10-09
DK3668972T3 (da) 2025-01-13
KR20200047588A (ko) 2020-05-07
EP4509135A2 (en) 2025-02-19
KR102806169B1 (ko) 2025-05-13
IL272715B1 (en) 2025-01-01
US20200347370A1 (en) 2020-11-05
WO2019036719A2 (en) 2019-02-21
EP3668972B8 (en) 2024-11-13
BR112020003403A2 (pt) 2020-08-25
SG11202001445XA (en) 2020-03-30
ES3008982T3 (en) 2025-03-25
US20200399622A1 (en) 2020-12-24
CA3073317A1 (en) 2019-02-21
JP2020534865A (ja) 2020-12-03
EP4509135A3 (en) 2025-05-07
EP3668972A2 (en) 2020-06-24
EP3668972A4 (en) 2021-04-21
US11046943B2 (en) 2021-06-29
IL272715B2 (en) 2025-05-01
US10696956B2 (en) 2020-06-30
AU2018318313A1 (en) 2020-03-19
US20200024585A1 (en) 2020-01-23
JP7577314B2 (ja) 2024-11-05
US11046942B2 (en) 2021-06-29
UA129696C2 (uk) 2025-07-09
US20210040461A1 (en) 2021-02-11
US10801019B1 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
US10801019B1 (en) Engineered DNase enzymes and use in therapy
Englert et al. Targeting NETs using dual-active DNase1 variants
CN102316893B (zh) 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
JP4451514B2 (ja) 血液凝固第ｖｉｉ因子改変体
Cioni et al. Use of exogenous enzymes in human therapy: approved drugs and potential applications
AU2006256891B2 (en) Use of the ideS proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
Jiang et al. 2025 clinical trials update on hemophilia, VWD, and rare inherited bleeding disorders
JP2020502133A (ja) 肺の繊維化を予防及び治療するための方法
CN108210904A (zh) 治疗动脉粥样硬化及其并发症的药物及其用途
US11058724B2 (en) Methods of using DNASE1-like 3 in therapy
HK40034165A (en) Engineered dnase enzymes and use in therapy
EA049198B1 (ru) СКОНСТРУИРОВАННЫЕ ФЕРМЕНТЫ ДНКазы И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
US20220241374A1 (en) Treatment of non-alcoholic steatohepatitis
Kolev et al. Targeting NETs using dual-active DNase1 variants
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
US20120065137A1 (en) Therapeutics for trauma induced factor v consumptive coagulopathy
HK1161138B (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
HK1161138A (en) Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CN101112358A (zh) 葡激酶肌肉注射剂及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034165

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200821

WD01 Invention patent application deemed withdrawn after publication